TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03598621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.0 mg/mL
Description: A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.34 mg/mL
Description: A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.34 mg/mL
Description: A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.34 mg/mL
Description: A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 2.0 mg/mL
Description: A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DV3372, 0.5 mg/mL
Description: DV3372 device will be used for administration of semaglutide 0.5 mg/mL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DV3372, 1.0 mg/mL
Description: DV3372 device will be used for administration of semaglutide 1.0 mg/mL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS290
Description: PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS290
Description: PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS290
Description: PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoPen®4
Description: NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
Study: NCT03628677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Study: NCT01122888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01160263

Intervention type: DRUG
Group type: OTHER
Intervention: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
Description: 123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.

Intervention type: DRUG
Group type: OTHER
Intervention: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
Description: 123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.

Intervention type: DRUG
Group type: OTHER
Intervention: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
Description: 123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.
Study: NCT04836923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIver FrailTy intervention (LIFT)
Description: Novel physical therapy intervention to decrease frailty in pre-transplant patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIver FrailTy intervention (LIFT)
Description: Novel physical therapy intervention to decrease frailty in pre-transplant patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Realistic Effort Action Planning intervention (REAP)
Description: This intervention is an interactive behavioral interviewing process to engage patients in their care
Study: NCT04254445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized training video
Description: Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
Study: NCT04021576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preventative training program
Description: complementary training of leg-, hip- and core-strength/stability
Study: NCT02230839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Restriction-Induced Weight Loss
Description: The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (\<30% of calories from fat) diet will be used as part of the weight loss intervention.
Study: NCT01316380

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 2.5 mcg
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 5 mcg
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
Study: NCT03272971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio-frequency Ablation
Description: The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
Study: NCT00003838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell replete PBPC allograft
Description: Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver \>5x10\^6 CD34+ cells/kg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell replete PBPC allograft
Description: Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver \>5x10\^6 CD34+ cells/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV MTX on days +1, +3, and +6 will be given
Study: NCT03628677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Study: NCT03903848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Single session of treadmill walking and resistance exercise
Study: NCT00003838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV MTX on days +1, +3, and +6 will be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade \> II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade \> II GVHD will have CSA discontinued regardless of chimerism results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade \> II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade \> II GVHD will have CSA discontinued regardless of chimerism results.

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
Study: NCT00879047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol placebo
Description: Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol placebo
Description: Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol placebo
Description: Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol placebo
Description: Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol placebo
Description: Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
Study: NCT03454724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
Description: MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
Description: MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience EES Everolimus Eluting Coronary Stent System
Description: Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience EES Everolimus Eluting Coronary Stent System
Description: Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
Study: NCT04409730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photographic Posture Analysis
Description: Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
Study: NCT03900663

Intervention type: DEVICE
Intervention: Anthropometric measures
Description: Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference

Intervention type: DEVICE
Intervention: Anthropometric measures
Description: Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference

Intervention type: DEVICE
Intervention: Anthropometric measures
Description: Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference

Intervention type: DEVICE
Intervention: Anthropometric measures
Description: Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference
Study: NCT04228445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%
Description: Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%
Description: Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline spray
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline spray
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: Placebo
Study: NCT02164604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of 0.03ml ranibizumab
Study: NCT03121482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC
Description: Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
Study: NCT01453933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
Study: NCT04306666

Intervention type: OTHER
Intervention: Regional anesthesia
Description: Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.

Intervention type: OTHER
Intervention: Regional anesthesia
Description: Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
Study: NCT01376895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROJECT POWER
Description: POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Power Health
Description: Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
Study: NCT03882853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative exercise group
Description: The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative exercise group
Description: The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tree pose added exercise group
Description: The group will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation, also be taught tree pose of yoga. Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
Study: NCT01503892

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Metanx
Description: Metanx- one tablet twice daily for twelve months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- one tablet twice daily for twelve months.
Study: NCT03749213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
Study: NCT06298760

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Knee Massage With Black Cumin Oil Group:
Description: The patients received a knee massage with black cumin oil once a week for approximately 30 minutes for 6 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Foot Reflexology Group With Black Cumin Oil
Description: The patients underwent foot reflexology with black cumin oil once a week for approximately 40 minutes for 6 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Applications were made with vaseline

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Applications were made with vaseline
Study: NCT00333424

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine
Description: 6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
Study: NCT01878227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme A
Description: Coenzyme A 400mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 200mg
Description: Fenofibrate 200mg per day
Study: NCT03858569

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active management of third stage of labor
Description: Active management of the third stage of the labor will be done administering oxytocin and cord traction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active management of third stage of labor
Description: Active management of the third stage of the labor will be done administering oxytocin and cord traction.
Study: NCT01856855

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy with Integrated Boost
Description: SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
Study: NCT02781415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture Session
Description: Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Titration
Description: Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal.